Literature DB >> 7272306

DNA double-stranded breaks in mammalian cells after exposure to intercalating agents.

W E Ross, M O Bradley.   

Abstract

Previous work has shown that exposing mouse L1210 cells to intercalating agents such as adriamycin, ellipticine and actinomycin D results in DNA single-stranded breaks and DNA-protein crosslinks. To characterize further the interaction between these drugs and intracellular DNA we have employed a modification of the alkaline elution technique which allows the detection of DNA double-stranded breaks. Ellipticine (1.25-5.0 microgram/ml) adriamycin (0.5-3.0 microgram/ml) and actinomycin D (1.5-3.0 microgram/ml) all caused double-stranded breaks in DNA from L1210 cells following a 1 h treatment. The number of double-stranded breaks found per single strand break was highest for ellipticine, despite the fact that this is least cytotoxic of the three drugs. By comparing the single and double strand break frequency caused by radiation to that caused by ellipticine, it appears that most if not all of the drug-induced single strand breaks observed actually represent double-strand breaks. We suggest that these double-strand breaks may result from the action of an intracellular enzyme, perhaps topoisomerase, which breaks both strans in concert to relieve the topological strain caused by drug intercalation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7272306     DOI: 10.1016/0005-2787(81)90145-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  32 in total

1.  A novel mouse model for ataxia-telangiectasia with a N-terminal mutation displays a behavioral defect and a low incidence of lymphoma but no increased oxidative burden.

Authors:  Andrew Campbell; Brittany Krupp; Jared Bushman; Mark Noble; Christoph Pröschel; Margot Mayer-Pröschel
Journal:  Hum Mol Genet       Date:  2015-08-26       Impact factor: 6.150

2.  Topoisomerase-specific drug sensitivity in relation to cell cycle progression.

Authors:  K C Chow; W E Ross
Journal:  Mol Cell Biol       Date:  1987-09       Impact factor: 4.272

3.  Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells.

Authors:  A Bredberg; M Brant; M Jaszyk
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 4.  Topoisomerases, new targets in cancer chemotherapy.

Authors:  J G Zijlstra; S de Jong; E G de Vries; N H Mulder
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

5.  Drosophila topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site.

Authors:  M Sander; T S Hsieh
Journal:  Nucleic Acids Res       Date:  1985-02-25       Impact factor: 16.971

6.  Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.

Authors:  Constance King; Henry Diaz; Darlene Barnard; David Barda; David Clawson; Wayne Blosser; Karen Cox; Sherry Guo; Mark Marshall
Journal:  Invest New Drugs       Date:  2013-10-10       Impact factor: 3.850

7.  ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia.

Authors:  Qingyi Tong; Huijuan You; Xintao Chen; Kongchao Wang; Weiguang Sun; Yufeng Pei; Xiaodan Zhao; Ming Yuan; Hucheng Zhu; Zengwei Luo; Yonghui Zhang
Journal:  Nucleic Acids Res       Date:  2018-04-20       Impact factor: 16.971

8.  Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.

Authors:  E M Nelson; K M Tewey; L F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

9.  A novel high-through-put assay for screening of pro-apoptotic drugs.

Authors:  Maria Hägg; Kenneth Bivén; Takayuki Ueno; Lars Rydlander; Peter Björklund; Klas G Wiman; Maria Shoshan; Stig Linder
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

10.  LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.

Authors:  Darlene Barnard; H Bruce Diaz; Teresa Burke; Gregory Donoho; Richard Beckmann; Bonita Jones; David Barda; Constance King; Mark Marshall
Journal:  Invest New Drugs       Date:  2015-11-27       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.